Effects of pharmacological suppression of plasminogen activator inhibitor-1 in myocardial remodeling after ischemia reperfusion injury.

Plasminogen activator inhibitor-1 (PAI-1) contributes to cardiac ventricular remodeling because migration of inflammatory cells and attenuation of extracellular matrix degradation are caused by plasmin and matrix metalloproteinase. However, the roles of PAI-1 in myocardial ischemia reperfusion (I/R) injury and the following inflammatory response have not yet been well elucidated. To clarify the role of PAI-1 in myocardial I/R injury, we used a specific PAI-1 inhibitor (IMD-1622) in a rat model. The left anterior descending coronary artery was ligated and reperfusion was performed by loosening the suture after 30 minutes of arterial occlusion. A single administration of IMD-1622 (20 mg/kg) or vehicle was given intraperitoneally and then the rats were sacrificed on day 1 or day 14 after I/R. Blood pressure, echocardiograms, histopathology, and molecular examination were performed. The examinations revealed that PAI-1 inhibitor showed limited effects on cardiac dysfunction and ventricular remodeling after I/R. We conclude that the pharmacological inhibition of PAI-1 may not affect ventricular remodeling after myocardial I/R injury.

[1]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[2]  A. Itai,et al.  Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. , 2004, Cardiovascular research.

[3]  Eric J. Topol,et al.  Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction , 2003, The Journal of experimental medicine.

[4]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[5]  M. Isobe,et al.  Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. , 2009, Cardiovascular research.

[6]  J. Winer,et al.  Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. , 1999, Analytical biochemistry.

[7]  G. Arteel,et al.  Critical Role of Plasminogen Activator Inhibitor-1 in Cholestatic Liver Injury and Fibrosis , 2006, Journal of Pharmacology and Experimental Therapeutics.

[8]  T. van der Poll,et al.  Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. , 2009, Kidney international.

[9]  P. Carmeliet,et al.  Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis , 2006, Circulation.

[10]  D. Yellon,et al.  Myocardial reperfusion injury. , 2007, The New England journal of medicine.

[11]  A. Itai,et al.  The Effects of Pharmacologic Plasminogen Activator Inhibitor-1 Inhibition in Acute and Chronic Rejection in Murine Cardiac Allografts , 2011, Transplantation.

[12]  B. Sobel,et al.  Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants , 2007, Histochemistry and Cell Biology.

[13]  A. Itai,et al.  Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction , 2007 .

[14]  F. Rosendaal,et al.  Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. , 2010, Blood.

[15]  V. Barak,et al.  The Relationship of Plasminogen Activator Inhibitor-1 Levels to the ST Deviation Pattern of Acute Myocardial Infarction , 2008, Cardiology.

[16]  M. Radomski,et al.  Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. , 2000, Circulation.

[17]  R. Dixon,et al.  Blockade of cell adhesion by a small molecule selectin antagonist attenuates myocardial ischemia/reperfusion injury. , 2003, European journal of pharmacology.

[18]  A. Itai,et al.  Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. , 2007, American journal of physiology. Heart and circulatory physiology.

[19]  M. Isobe,et al.  Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats. , 2007, Journal of molecular and cellular cardiology.

[20]  A. Itai,et al.  A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis. , 2008, Expert opinion on therapeutic targets.

[21]  N. Turner,et al.  Cardiac fibroblasts: at the heart of myocardial remodeling. , 2009, Pharmacology & therapeutics.

[22]  Bernd R Binder,et al.  uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view , 2007, Thrombosis and Haemostasis.

[23]  A. Itai,et al.  A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration. , 2008, Expert opinion on therapeutic targets.

[24]  G. Arteel.  New role of plasminogen activator inhibitor‐1 in alcohol‐induced liver injury , 2008, Journal of gastroenterology and hepatology.

[25]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[26]  Toshiyuki Yamamoto,et al.  Monocyte Chemoattractant Protein-1 Enhances Gene Expression and Synthesis of Matrix Metalloproteinase-1 in Human Fibroblasts by an Autocrine IL-1α Loop1 , 2000, The Journal of Immunology.

[27]  E. Abraham,et al.  PAI-1 inhibits neutrophil efferocytosis , 2008, Proceedings of the National Academy of Sciences.

[28]  A. Itai,et al.  The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. , 2008, Expert opinion on therapeutic targets.

[29]  T. Yamamoto,et al.  Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. , 2000, Journal of immunology.

[30]  M. Isobe,et al.  Clarithromycin attenuates myocardial ischemia–reperfusion injury , 2010, Expert opinion on therapeutic targets.

[31]  A. Itai,et al.  Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury , 2004 .